|
注册号: Registration number: |
ChiCTR2500110301 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-11 15:29:58 |
|
注册时间: Date of Registration: |
2025-10-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
老年肺炎住院患者的衰弱发病率与危险因素分析 |
|
Public title: |
Analysis of the Incidence and Risk Factors of Frailty in Elderly Inpatients with Pneumonia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
老年肺炎住院患者的衰弱发病率与危险因素分析 |
|
Scientific title: |
Analysis of the Incidence and Risk Factors of Frailty in Elderly Inpatients with Pneumonia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈漂 |
研究负责人: |
陈漂 |
|
Applicant: |
Chen Piao |
Study leader: |
Chen Piao |
|
申请注册联系人电话: Applicant telephone: |
+86 135 3831 1864 |
研究负责人电话:
Study leader's |
+86 135 3831 1864 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
piao586chen@126.com |
研究负责人电子邮件: Study leader's E-mail: |
piao586chen@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省茂名市茂南区为民路101号 |
研究负责人通讯地址: |
广东省茂名市茂南区为民路101号 |
|
Applicant address: |
No. 101, Weimin Road, Maonan District, Maoming City, Guangdong Province |
Study leader's address: |
No. 101, Weimin Road, Maonan District, Maoming City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
茂名市人民医院 |
||
|
Applicant's institution: |
Maoming People's Hospital |
||
|
研究负责人所在单位: |
茂名市人民医院 |
||
|
Affiliation of the Leader: |
Maoming People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PJ2025MI-K140-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
茂名市人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Maoming People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-22 00:00:00 | ||
|
伦理委员会联系人: |
李兰 |
||
|
Contact Name of the ethic committee: |
Li Lan |
||
|
伦理委员会联系地址: |
广东省茂名市茂南区为民路101号 |
||
|
Contact Address of the ethic committee: |
No. 101, Weimin Road, Maonan District, Maoming City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 2922871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
茂名市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Maoming People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省茂名市茂南区为民路101号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 101, Weimin Road, Maonan District, Maoming City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-finance |
||||||||||||||||||||||
|
研究疾病: |
老年肺炎;老年衰弱 |
||||||||||||||||||||||
|
Target disease: |
Senile Pneumonia; Senile Frailty |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
评估老年肺炎住院患者的衰弱发病率,分析老年肺炎住院患者的衰弱危险因素,初步探索老年肺炎特异性衰弱评估工具,为老年肺炎患者的衰弱筛查和干预提供依据,改善患者预后,降低医疗负担。 |
||||||||||||||||||||||
|
Objectives of Study: |
To assess the incidence of frailty in elderly inpatients with pneumonia, analyze the risk factors for frailty in these patients, preliminarily explore pneumonia-specific frailty assessment tools for the elderly, provide a basis for frailty screening and intervention in elderly pneumonia patients, improve patient prognosis, and reduce medical burden. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.ADL<=40分的重度失能者; 2.正在服用可能产生类衰弱症状药物者; 3.严重认知障碍或无法配合评估者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Severely disabled individuals with an ADL score of 40 or less; 2. Those who are taking medications that may cause debilitating symptoms; 3. Those with severe cognitive impairment or who are unable to cooperate with the assessment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-01 00:00:00至 To 2028-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-10-11 00:00:00 至 To 2027-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:研究采用病例记录表收集原始数据,利用Epidata3.1建立数据库。 数据管理:(1)研究者必需保证数据真实、完整、准确。(2)研究记录做任何更正时只能划线,旁注改后的数据,说明理由,由研究者签名并注明日期,不得擦涂、覆盖原记录。(3)实验室检查项目齐全。(4)有关受试者数据应以受试者编码方式记录,受试者只能通过受试者编码或其姓名首字母缩写识别。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: The study uses the case record table to collect raw data and use Epidata3.1 to establish a database. Data management: (1) Researchers must ensure that the data is true, complete and accurate. ( 2) When any corrections can be made in the research record, it can only be underlined, and the revised data should be noted to explain the reasons. The researcher should sign and date, and the original record shall not be erased or overwritten. ( 3) Laboratory inspection items are complete. ( 4) The relevant subject data should be recorded in the form of subject code, and the subject can only be identified by the subject code or its initials. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |